Mirror Bio is moving to the new Bio Park in Har Hozvim
Mirror Biologics is building a 1200m² GMP cell production and research facility in Har Hotzvim’s Bio Park. The new facility will produce AlloStim, a patented,
Neteera- 1 of 10 Best 2022 Patient Monitoring Solution Providers According to Insight Care
Neteera was chosen as one of the Best Patient Monitoring Solution Providers by Insight Care for 2022. Neetera Technologies has developed an AI-powered nursing assistant that
VOTIS Subdermal Imaging Technologies Begins Pilot Feasibility Study at Hadassah Med Center
VOTIS Subdermal Imaging Technologies Ltd. has started enrolling the first patients in the feasibility study of its PedCheck™ device at Hadassah Medical Center in Jerusalem,
Oramed Completes Patient Enrollment of its Pivotal Phase 3 Oral Insulin Study
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, has completed patient enrollment for
Image Navigation revolutionizes the line of minimally invasive dental implant treatments
Image Navigation revolutionizes the line of minimally invasive dental implant treatments with its new IGI 2.0, groundbreaking technology that ensures real-time surgical navigation for maximum
Omnix Medical Starts Phase I Clinical Trial of their Novel Antimicrobial Agent
New mechanism of action (MoA) addressing global increase of antimicrobial resistance (AMR) burden and shortage of potent anti-infectives JERUSALEM, Israel, April XX, 2022 —
FDA Clearance to Gamida Cell for GDA-201 Treatment of Follicular & Diffuse Large B Cell Lymphomas
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in nicotinamide (NAM) -enabled cell therapies for patients with hematologic and solid cancers, has received the green light
Olive Diagnostics AI Urine Analysis Readable on The Apple Watch
Jerusalem-based Olive Diagnostics’s KG system is the world’s first 100 percent passive non-invasive real-time urine analysis sensor that can be hooked up to any toilet. This
KAHR Published Preclinical Data Indicating Treatment Potential of Their Anti-CD47 Fusion Protein
KAHR, a Jerusalem clinical-stage cancer immunotherapy company, has just announced the publication of their preclinical data that supports the development of DSP107. DSP107 is a
